Home > Insider Trading > Filing (0001209191-15-084051)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1567514	Intra-Cellular Therapies Inc.	ITCI	Pharmaceutical Preparations (2834)	364742850

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1216955	S Joel Marcus	C/O Alexandria Real Estate Equities,Inc. 385 East Colorado Boulevard, Suite 299 Pasadena CA 91101		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-12-04	30,000	$55.96	1,253,856	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2015-12-07	15,075	$52.15	1,238,781	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2015-12-07	24,925	$53.78	1,213,856	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2015-12-08	22,700	$54.80	1,191,156	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	18,722	Direct
Common Stock	15,742	Indirect	Held by the Joel S. Marcus and Barbara A. Marcus Family Trust

Footnotes

Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.95 to $56.00, inclusive. The reporting person undertakes to provide to Intra-Cellular Therapies, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) of this Form 4.